Antineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsChemotherapy, AdjuvantRadiation DosageRadiation, IonizingRadiation InjuriesDoxorubicinCisplatinCombined Modality TherapyDose-Response Relationship, RadiationNeoplasmsCell Line, TumorRadiation ToleranceDrug Screening Assays, AntitumorRadiationDrug Resistance, NeoplasmRadiation ProtectionEtoposideRadiation MonitoringTreatment OutcomeCyclophosphamideBreast NeoplasmsAntineoplastic Agents, PhytogenicApoptosisPaclitaxelAntibiotics, AntineoplasticCell SurvivalDisease-Free SurvivalRadiotherapyLung NeoplasmsNeoadjuvant TherapySurvival AnalysisNeoplasm StagingRadiation OncologyDrug Delivery SystemsVinblastinePrognosisCamptothecinTumor Cells, CulturedMethotrexateTime FactorsAntimetabolites, AntineoplasticSurvival RateDrug Administration ScheduleKiller Cells, NaturalOrganoplatinum CompoundsXenograft Model Antitumor AssaysDose-Response Relationship, DrugCarboplatinRadiotherapy DosageBleomycinMice, NudeAntineoplastic Agents, AlkylatingTaxoidsGamma RaysDrug CarriersDNA DamageRadiation PneumonitisCosmic RadiationRadiation Injuries, ExperimentalNeoplasm Recurrence, LocalCell ProliferationDeoxycytidineAdenocarcinomaRadiation-Sensitizing AgentsDrug Resistance, MultipleP-GlycoproteinNeoplasms, Radiation-InducedDaunorubicinAnthracyclinesBrain NeoplasmsRadiotherapy, AdjuvantOvarian NeoplasmsBackground RadiationDrug SynergismMitomycinCarcinoma, Non-Small-Cell LungClinical Trials as TopicMitoxantroneInduction ChemotherapyMolecular StructureEllipticinesPlatinumInhibitory Concentration 50Neoplasm MetastasisFollow-Up StudiesUltraviolet RaysIfosfamideCytarabineGene Expression Regulation, NeoplasticColonic NeoplasmsDacarbazineCell CycleRadiometryDrug DesignCarcinoma, Squamous CellPlatinum CompoundsTumor Suppressor Protein p53Colorectal NeoplasmsLiver Neoplasms